Financial reports
20-F
2023 FY
Annual report (foreign)
30 Aug 23
20-F
2022 FY
Annual report (foreign)
30 Aug 22
20-F
2021 FY
Annual report (foreign)
31 Aug 21
20-F
2020 FY
Annual report (foreign)
22 Oct 20
20-F
2019 FY
Annual report (foreign)
3 Oct 19
20-F
2018 FY
Annual report (foreign)
31 Oct 18
20-F
2017 FY
Annual report (foreign)
31 Oct 17
20-F/A
2016 FY
Annual report (foreign) (amended)
4 Nov 16
20-F
2016 FY
Annual report (foreign)
28 Oct 16
20-F
2015 FY
Annual report (foreign)
13 Nov 15
Current reports
6-K
ASX Market Announcement
11 Sep 24
6-K
Genetic Technologies receives Nasdaq notice of noncompliance with the $1 minimum bid price requirement
28 Aug 24
6-K
Global launch of geneType™ on wholly owned EasyDNA platform
15 Aug 24
6-K
Appendix 4C & Quarterly Business Update – June 2024
31 Jul 24
6-K
Strategic restructure to focus on USA sales growth
26 Jul 24
6-K
Current report (foreign)
28 Jun 24
6-K
Current report (foreign)
28 Jun 24
6-K
ASX Market Announcement
21 Jun 24
6-K
ASX Market Announcement
5 Jun 24
6-K
GTG Launches Revolutionary geneType Test covering 100% Risk of Breast and Ovarian Cancer
29 May 24
Registration and prospectus
424B5
Prospectus supplement for primary offering
22 Apr 24
F-3
Shelf registration (foreign)
20 Dec 23
424B3
Prospectus supplement
7 Dec 23
424B3
Prospectus supplement
4 Dec 23
424B3
Prospectus supplement
30 Nov 23
424B5
Prospectus supplement for primary offering
7 Feb 23
424B5
Prospectus supplement for primary offering
25 Jan 21
424B5
Prospectus supplement for primary offering
20 Jul 20
424B4
Prospectus supplement with pricing info
28 May 20
F-1/A
Registration statement (foreign) (amended)
12 May 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
28 May 24
EFFECT
Notice of effectiveness
5 Jan 24
CORRESP
Correspondence with SEC
2 Jan 24
UPLOAD
Letter from SEC
27 Dec 23
EFFECT
Notice of effectiveness
27 May 20
CORRESP
Correspondence with SEC
21 May 20
EFFECT
Notice of effectiveness
24 Mar 20
CORRESP
Correspondence with SEC
20 Mar 20
UPLOAD
Letter from SEC
19 Mar 20
UPLOAD
Letter from SEC
20 Dec 19
Ownership
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G
CVI Investments, Inc.
13 Feb 23
SC 13G
INTRACOASTAL CAPITAL, LLC
4 Jun 20
SC 13G
INTRACOASTAL CAPITAL, LLC
28 Apr 20
SC 13G/A
Genetic Technologies LTD
13 Feb 19
SC 13G
Genetic Technologies LTD
14 Feb 18
SC 13G/A
Genetic Technologies LTD
9 Feb 18
SC 13G/A
Genetic Technologies LTD
8 Jan 18
SC 13G/A
Genetic Technologies LTD
14 Feb 17
SC 13G/A
Genetic Technologies LTD
10 Feb 17